secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2022-10-31T23:59:59+00:00
Accession:  0000950170-22-020535
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto GB1211 reduces signs of liver impairment in GULLIVER-2 trial; data presented at AASLD
--------------------------------------------------------------------------------

- GB1211 well-tolerated with predictable PK; showed reductions in liver enzymes and FibroScan, indicating decreased inflammation and steatosis.
- Part 2 data selected as 'Best of The Liver Meeting' in NASH/NAFLD category.
- Preclinical rabbit model: GB1211 significantly reduced inflammation, fibrosis, and fat vs control.
- Galecto to host webinar Nov 8, 2022 at 8:00 AM ET to discuss expanded topline data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017022020535/0000950170-22-020535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017022020535/glto-20221031.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer